Navigation Links
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
Date:2/24/2009

PRINCETON, N.J., Feb. 24 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced the appointment of Dr. Marcel Rozencweig as Senior Executive Vice President for Clinical Affairs. Prior to joining Sopherion, Dr. Rozencweig was a key Clinical Development Consultant to the Company and a member of the Sopherion Protocol Development Team for Myocet.

"I am excited to continue to contribute to the development of Myocet," said Dr. Rozencweig. "Myocet has the potential to be a valued addition to the first-line treatment regimen for metastatic breast cancer, particularly in patients with HER-2 overexpression."

Dr. Rozencweig was previously with GPC-Biotech since 2001. He has 18 years of experience with Bristol-Myers Squibb, where he held several senior leadership positions in drug development and strategic planning, including Vice President, Oncology, Infectious Diseases and Immunology Clinical Research; and Vice President, Strategic Planning and Portfolio Management.

"Dr. Rozencweig's world-renowned experience in oncology drug development is an ideal fit for Sopherion as we move Myocet forward," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters Taxol(R) and Paraplatin(R) (carboplatin)."

Dr. Rozencweig is an Adjunct Associate Professor of Medicine at New York University and has authored or co-authored more than 200 scientific publications.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patien
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cell Therapeutics to Resume Trading on MTA and NASDAQ
2. United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results
3. Cell Therapeutics Updates Shareholders on Trading
4. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
5. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
7. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
8. Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
9. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
11. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader ... quality regarding heating, cooling and plumbing services in the ... the “Queen of Clean” for impressive contractor services in ... over the years for providing outstanding quality customer service ... services for both homeowners and businesses. Linda Cobb, known ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... issue of American Journal of Preventive Medicine says that there ... ,These conclusions were arrived at by researchers at ... Centers for Disease Control and Prevention. They monitored data of ... Factor Surveillance System survey. This particular survey covered 22 states ...
... appearing in the online journal Cancer says that elderly white ... to develop full blown melanoma regardless of their exposure to ... study found that women in the age group of 50 ... carcinoma or squamous cell carcinoma of the skin, had a ...
... attempt to rapidly eliminate milder strains of avian influenza virus ... been proposed to broaden the target of the European Union ... been taken by agricultural ministers of the 25 different countries ... the proposal, it was agreed to boost the currently existing ...
... into the oral HIV tests which have given false results. ... California and New York health centers. The rapid OraQuick Advance ... minutes. The test had gained popularity as blood samples are ... ,Complaints are being investigated by officials belonging to ...
... Hickok, neuroscientist, professor of cognitive sciences at the University ... The National Institute of //Deafness and Other Communication Disorders ... Health ($2.4 million for 5 years). ,This ... brain converts sound waves into meaningful language. ...
... health hospitals are flooded with patients with psychiatric disorders. The ... 12% in the past 4 years. ,This ... health facilities. ,According to the Australian Institute of ... specialized psychiatric hospitals decreased by 5%. ,But the ...
Cached Medicine News:Health News:Detection of Weak strains of bird flu virus – Target of European Unio 2Health News:$2.4 Million Grant To Unravel The Mystery Of Language Recognition. 2Health News:Community hospitals inundated with Psychiatric care cases (12%) 2
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... will present new data across its portfolio representing ... rare and difficult-to-treat cancers.  These results will be ... for Medical Oncology (ESMO) Congress in Milan, Italy ... http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO) "Pfizer ...
... Oct. 7 Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) ... treatment-naive patients with primary immunodeficiency (PI) and may ... therapy in the newly diagnosed, according to data ... European Society for Immunodeficiencies. The study found that ...
Cached Medicine Technology:Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 2Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 3Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 4Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 5Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 6Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 7Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 8Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 9Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 10Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 11Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 12Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 2Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 3Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 4
... Grade PRODUCT SPECIFICATIONS Form: Granular, free-flowing powder EEO(-m r ... Point (3%): less than or equal to 35.5C ... 80C Gel Strength (1.5%): greater than or equal ... greater than or equal to 1500 gm/cm 2 ...
... sulfate (SO 4 ) ≤ 6000 mg/kg Cation traces: ... ≤ 10 mg/kg Cr ≤ 10 mg/kg Cu ≤ ... mg/kg Mg ≤ 10 mg/kg Mn ≤ 10 mg/kg ... ≤ 10 mg/kg Zn ≤ 10 mg/kg Special ...
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
Medicine Products: